Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.69%
SUMITOMO MIT SMFG
3.61%
VANTIV INC VNTV
3.00%
TOKIO MARINE TKOMY
2.99%
NIPPON TELEG NTT
2.88%

Sirona Introduces CEREC Omnicam

by Zacks Equity Research

August 21, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dental technology leader Sirona Dental Systems, Inc. (SIRO - Snapshot Report) recently introduced its latest intraoral camera, CEREC Omnicam. This new product is slated to enhance the company’s leading-edge CEREC CAD/CAM systems.

CEREC Omnicam is groundbreaking as it can capture 2D as well as 3D intraoral data unlike other CAD/CAM cameras available in the market. Sirona’s newest offering possesses innovative inbuilt features such as a handpiece which will minimize physical effort along with special optics to ensure inner access. Another progressive feature is that the CEREC Omnicare can deliver half-arch and full-arch observations at high speed in full color, ranked as another Sirona ‘first’.

Additional features of the CEREC Omnicam include accuracy, and anti-shake aspect to delete poor images automatically. It has powder free finish to enhance operating efficiency. CEREC Omnicam is designed with a slender, rounded camera to allow effortless rotation and excellent lens position to capture images in the intraoral recess.

According to Sirona, the development of CEREC Omnicam underlines its commitment towards product innovation. The nonpareil feature of the camera is that it eliminates the trade-off that clinicians always encounter between operating efficiency and accuracy.

Management believes that CEREC systems are the most forward looking product in the industry. The company’s CAD/CAM segment revenues came in at $306.7 million (34% of total revenues) in 2011, up 17.8% year over year. Growth was helped by strong sales of CEREC systems. The introduction of CEREC Omnicam is expected to bolster the sales of the company’s CAD/CAM segment.

Sirona is a leading innovator and manufacturer of dentistry products. The company’s global sales and financial position will continue to boost its growth momentum.

However, the contagion of international macroeconomic problems and the company’s reliance on its distributors such as Patterson Dental, a unit of Patterson Companies (PDCO - Analyst Report), and Henry Schein, Inc. (HSIC - Snapshot Report) are cause for concern. Sirona directly competes with DENTSPLY International Inc. (XRAY - Analyst Report) in the dental industry.

Sirona currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.